Abstract Phenazines are a diverse class of nitrogen‐containing heterocycles with a wide range of chemical structures and biological applications. We have developed a synthetic route for phenazines through a palladium‐catalyzed reductive cyclization of 2‐nitro‐ N ‐phenylanilines using either gaseous carbon monoxide or phenyl formate as an in situ CO source as efficient and cheap reductants. Our protocol offers a practical alternative to existing methods, achieving good yields without relying on large amounts of strongly reducing or oxidizing agents. Moreover, it minimizes the formation of unwanted byproducts, which is a common drawback in traditional phenazine synthesis. The key advantages of this protocol include the use of a simple Pd‐catalyst in the presence of 1,10‐phenanthroline (Phen), an inexpensive and commercially available ligand. These features make our method very convenient for phenazine synthesis. An uncommon inverse correlation between catalyst loading and product selectivity, as well as key differences between the use of gaseous CO and its surrogate, will also be discussed.
Galiè et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: